The Infinion 16 Lead, which is currently available in the US, will be introduced in CE Mark countries immediately.
SCS leads are designed to deliver electrical pulses from an implantable pulse generator to the spinal cord to mask pain signals to the brain (known as paresthesia). By providing twice the number of contacts than any previous percutaneous lead, the Infinion 16 Lead is designed to offer more coverage of the spinal cord for the management of chronic pain.
Maulik Nanavaty, senior vice president and president of the Boston Scientific Neuromodulation division, said: “The Infinion 16 Lead is the latest advance in SCS lead technology and an exciting addition to our unrivaled percutaneous lead portfolio.
“We believe that the European launch of the Infinion 16 Lead, coupled with increased awareness of pain management treatment alternatives, will allow us reach a wider patient population. Boston Scientific continues its commitment to innovation by offering pain management physicians more choices to help optimize pain relief for their patients.”
Kliment Gatzinsky of the neurosurgery department at the Sahlgrenska University Hospital in Guldheden, Sweden, said: “I appreciate that for the first time, it is possible to place 16 contacts with a single percutaneous lead using a small insertion needle. This lead will provide me with more options to optimize the paresthesia coverage to bring relief for chronic pain patients.”
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.